BridgeMD
New treatment option for Multiple System Atrophy
Official title An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
ClinicalTrials.gov ID: NCT07197866
What this study is testing
What is TEV-56286?
TEV-56286 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for multiple system atrophy.
Also referred to as Emrusolmin.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286.
- Phase 2: a mid-size study of how well it works
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 and older
You may be able to join if
- Completion of the treatment period and the week 48(V9) visit of the blinded trial (TV56286-NDG-20039) whilst remaining compliant with trial...
- Females of childbearing potential may be included only if they have a negative pregnancy test at the baseline visit
- Females of childbearing potential whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for...
- Males who are potentially fertile/reproductively competent (not surgically [eg, vasectomy] or congenitally sterile) and their female partners who are...
You likely can't join if
- Is a female participant who is pregnant, plans to become pregnant, or is breastfeeding during the trial
- Is of a vulnerable population (eg, people kept in detention or jail)
- Is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this trial Note - Additional criteria...
The study team makes the final eligibility decision.
Where it's taking place
- La Jolla, California, United States
- Boca Raton, Florida, United States
- Tampa, Florida, United States
- New York, New York, United States
- Spokane, Washington, United States
- Bordeaux, France
- Paris, France
- Toulouse, France
- Dresden, Germany
- Düsseldorf, Germany
- Kassel, Germany
- Marburg, Germany
- München, Germany
- Münster, Germany
- Haifa, Israel
- Tel Aviv, Israel
- Bologna, Italy
- Milan, Italy
- Roma, Italy
- Salerno, Italy
+ 7 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include La Jolla, California, United States; Boca Raton, Florida, United States; Tampa, Florida, United States; New York, New York, United States; Spokane, Washington, United States; Bordeaux, France and 21 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.